Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

ASH 2017 Recap: These Were the Big Winners and Losers

TheMotleyFool 
0 0 15.12.17
ASH 2017 Recap: These Were the Big Winners and Losers
 
ASH 2017 Recap: These Were the Big Winners and Losers

The American Society of Hematology's (ASH) conference is one of biopharma's biggest annual events. This year's meeting was packed with market-moving presentations, but perhaps the biggest showstopper was data from companies working on gene therapies.

For example, bluebird bio (NASDAQ: BLUE), Juno Therapeutics (NASDAQ: JUNO), Spark Therapeutics (NASDAQ: ONCE), and BioMarin (NASDAQ: BMRN) unveiled trial results for therapies that could someday become billion-dollar blockbusters. Investors didn't react to each company's results in the same way, though. Juno Therapeutics and Spark Therapeutics saw their share prices stagger, while bluebird bio's shares soared.

In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and contributor Todd Campbell discuss how gene therapies at these companies could reshape cancer and hemophilia treatments, and why investors reacted to the news the way they did.

Continue reading


Source: Fool.com

Juno Therapeutics Inc. Stock

-
-


Show more
Like: 0
JUNO
Share

Comments

Not a member yet? Sign up for free!